Sorry, you need to enable JavaScript to visit this website.

Join Pfizer in the Fight Against Cancer

Boxing gloves held up high announcing win

Cancer is one of the most serious health challenges of our time. Nearly 41% of Americans will receive a cancer diagnosis during their lifetime, and it still ranks as the second leading cause of death in the country.1,2 At Pfizer, we’re fighting to change those numbers with numbers of our own:

  • 8: the number of cancer breakthrough medicines we’re aiming to deliver by 2030
  • 40: the percent share of Pfizer’s research and development budget put towards cancer research
  • 2X: the number of patients expected to receive a Pfizer cancer medicine by 2030 compared to today3

One of our most exciting areas of research are antibody-drug conjugates (ADCs). ADCs specifically target cancer cells to deliver cancer-killing drugs directly to tumors, limiting damage to healthy cells and potentially limiting side-effects for patients. Pfizer is accelerating the next wave of ADC development so that more patients may have access to these breakthrough drugs, which may help improve outcomes.

To truly advance in our fight against cancer, we understand that it takes more than just breakthrough medicines. It also requires greater awareness of cancer prevention and early detection, which is why we need everyone to get in the ring with us.

On Sunday, we’ll be highlighting the fight against cancer in our new ad that will air during the big NFL broadcast. Debuting during one of the biggest television events of the year, the ad spotlights Pfizer’s commitment to developing cancer breakthroughs and aims to inspire the public to join us. The millions watching the Big Game will see the galvanizing spot, which is sure to help us make this fight even bigger; in just 60 seconds, we can ask more than 120 million people to unite with Pfizer and make an even bigger impact.

Awareness is the first step. Millions of Americans are at an increased risk of developing cancer without even knowing it. Understanding their risk factors gives people the knowledge to take action and detect cancer early, when it's most treatable. We’re working with our partners at the American Cancer Society (ACS) to make this easier than ever.

Enter PfizerForAll.com, our platform dedicated to making healthcare a more seamless experience. This hub will now offer access to American Cancer Society CancerRisk360™, an assessment tool that empowers people to join the fight against cancer, right where they are.

Developed by the American Cancer Society, the questionnaire makes it simple for people to learn more about their cancer risk factors, considering family history, lifestyle habits, environmental exposures, and medical conditions. The assessment will then guide users to a personalized set of recommendations and insights about prevention, early detection, and lifestyle changes.

In addition to the American Cancer Society CancerRisk360™ assessment, PfizerForAll also contains health questionnaires for atrial fibrillation (AFib), migraine, and vaccines eligibility.

Making the American Cancer Society CancerRisk360™ assessment easily accessible through PfizerForAll is part of Pfizer’s ongoing commitment to fighting cancer. Our fight has already resulted in game-changing developments in cancer care, but we’re not done yet. We’re working to ensure that more people who have cancer will have access to breakthrough treatments, and that fewer people ever face a cancer diagnosis at all.

Cancer doesn’t fight fair, but if we work together, we can fight back and one day deliver its final blow.

 


[1] Cancer Statistics. National Cancer Institute. May 9, 2024. Accessed January 31, 2025. https://www.cancer.gov/about-cancer/understanding/statisticsextlink label

[2] Cancer Deaths. National Center for Health Statistics. June 2023. Accessed January 31, 2025. https://www.cdc.gov/nchs/hus/topics/cancer-deaths.htmextlink label

[3] A Conversation with Chris Boshoff: Leading Pfizer’s Oncology Organization. Pfizer. May 29, 2024. Accessed January 28, 2025. https://insights.pfizer.com/chris-boshoff/